The pathogenesis of rheumatoid arthritis (RA), a chronic autoimmune disease, involves accumulation of T lymphocytes in the synovial compartment and destruction of cartilage and bone.1–3 Several antirheumatic drugs are available in the market including two monoclonal antibody (mAb) drugs against tumor necrosis factor-α, namely, Infliximab (Centocor) and Adalimumab (Abbott). This evidence concerns the gene TNF and rheumatoid arthritis.